NCT04075396View on ClinicalTrials.gov

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

January 8, 2021

Study Completion Date

November 14, 2022

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Lazertinib

Participants will receive Lazertinib tablets once daily.

Trial Locations (9)

8035

Hosp Univ Vall D Hebron, Barcelona

10461

Montefiore Medical Center, The Bronx

28009

Hosp. Gral. Univ. Gregorio Maranon, Madrid

29010

Hosp Virgen de La Victoria, Málaga

32804

Advent Health Orlando, Orlando

33612

Moffitt Cancer Center, Tampa

37211

Tennessee Oncology, Nashville

91010

City of Hope, Duarte

M20 4BX

The Christie Nhs Foundation Trust, Manchester

All Listed Sponsors

collaborator

Yuhan Corporation

INDUSTRY

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04075396 - A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter